Based on clinical trial data, abatacept was not associated with increased malignancy risks in RA or PsA; observational data indicated a higher risk vs other b/tsDMARDs.

Milan Kalawadia, CEO, North America, at Dr. Reddy’s Laboratories, goes inside the company’s new growth initiatives—and ...

"Other" biologics included abatacept (Orencia), rituximab (Rituxan), sarilumab (Kevzara), and tocilizumab (Actemra). TNF inhibitors used in JAK-pot registries included adalimumab, etanercept ...

However, specific combinations such as abatacept with Janus kinase (JAK) inhibitors may be associated with increased risks. Researchers conducted an observational study using the health data ...

During his tenure at BMS, Dr. Banerjee served as the global lead for mid- to late-stage clinical development of Sotyktu (deucravacitinib), Orencia (abatacept) and clazakizumab (anti-IL-6 antibody) for ...

Biological and targeted synthetic DMARDs were split into five classes: TNF inhibitors, interleukin (IL)-6 inhibitors, JAK inhibitors, rituximab (Rituxan, Genentech) and abatacept (Orencia ...

Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies ...

During his tenure at BMS, Dr. Banerjee served as the global lead for mid- to late-stage clinical development of Sotyktu (deucravacitinib), Orencia (abatacept) and clazakizumab (anti-IL-6 antibody ...